** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise ~8% to $38.43 premarket
** On Thursday, IONS said the U.S. FDA approved co's genetic disorder drug, olezarsen, to treat familial chylomicronemia syndrome (FCS)
** FCS is a condition that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides
** Brokerage TD Cowen forecasts peak sales of $82 mln in FY32 for FCS market
** 17 of 25 brokerages rate the stock "buy" or higher, 7 "hold" and 1 "sell"; their median PT is $62 - LSEG
** As of last close, stock has fallen 29.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。